Real-world cohort study confirms clinical benefits of sacituzumab govitecan in metastatic triple-negative breast cancer, suggesting implications for routine practice.
In this largest real-world cohort, the clinical benefit of SG observed in the ASCENT trial was confirmed under routine practice conditions. Poor performance status and liver metastases predicted inferior outcomes, while certain treatment-related AEs warrant further investigation.
No takes yet. Share an insight, caveat, or question.
Pieniążek et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: